Clearmind Medicine expands global clinical trial targeting AUD market

Clearmind Medicine (CMND) announced the addition of Hadassah-University Medical Center, Jerusalem, Israel, as a new clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder, AUD. The trial site at Hadassah-University Medical Center will be led by Prof. Yossi Karko, Director of the Center for Clinical Research, joining other prestigious institutions participating in the trial, including Yale School of Medicine’s Department of Psychiatry and Johns Hopkins University School of Medicine in the United States, as well as Tel Aviv Sourasky Medical Center and IMCA in Israel. The ongoing first-in-human trial is designed to evaluate the safety, tolerability, and pharmacokinetics of CMND-100, while also exploring its potential to reduce alcohol cravings and consumption in individuals diagnosed with AUD. The inclusion of additional leading institutions is expected to enhance patient recruitment, accelerate data collection, and increase the statistical power of the study.